Showing 2551-2560 of 5956 results for "".
- Fera Pharmaceuticals Obtains Orphan Drug Designation from the FDA for Naproxcinod for the Treatment of Sickle Cell Diseasehttps://modernod.com/news/nicoxs-partner-fera-pharmaceuticals-obtains-orphan-drug-designation-from-the-us-fda-for-naproxcinod-for-the-treatment-of-sickle-cell-disease/2480673/Nicox SA and Fera Pharmaceuticals announced that the FDA has granted Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an estimated 100,000 Americans. Naproxcinod is a nitr
- Lensar Submits FDA 510(k) Application for ALLYhttps://modernod.com/news/lensar-announces-us-food-and-drug-administration-acceptance-of-510k-submission-for-ally/2480671/Lensar announced that the FDA has accepted its 510(k) submission for its next-generation ALLY Adaptive Cataract Treatment System for review. The submission is the first stage of a planned, two-step commercial release s
- TearSolutions Meets with FDA and Announces Next Steps in the Development of Lacripephttps://modernod.com/news/tearsolutions-meets-with-fda-and-announces-next-steps-in-the-development-of-lacripep/2480661/TearSolutions, the developer of a replacement therapy for the treatment of dry eye disease (DED) called Lacripep, announced that in late 2021 it received official minutes from a Type C meeting with the FDA regarding the development of Lacripep for the treatment of DED and is planni
- Italian Patients Receive Samsara Vision’s SING IMT, a New Technology for Age-Related Macular Degenerationhttps://modernod.com/news/italian-patients-receive-samsara-visions-sing-imt-a-new-technology-for-age-related-macular-degeneration/2480658/Samsara Vision announced the first three successful clinical cases in Italy using its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) for people living with late-stage, age-related macular degeneration (AMD). The SING IMT was successfully implanted in patients
- Lensbox Launches 480+ First-to-Market Eye Care Patient Experience Centers in the US and Canadahttps://modernod.com/news/lensbox-launches-480-first-to-market-eyecare-patient-experience-centers-in-the-us-and-canada/2480652/Lensbox has announced the launch of 480+ Lensbox EyeDocs. The "bricks and clicks technology" features fully automated patient experience centers that integrate with the Lensbox first-to-market app, tying in tele-optometry, e-commerce, and point-of-sale technology for
- EssilorLuxottica Introduces New Leonardo Myopia Certification Programhttps://modernod.com/news/essilorluxottica-introduces-new-leonardo-myopia-certification-program/2480646/As part of its efforts to advance myopia education, EssilorLuxottica launched its new Leonardo myopia certification program in the US with a su
- Panelists Named for “Making Contact Lens Compliance Stick” Eventshttps://modernod.com/news/panelists-named-for-making-contact-lens-compliance-stick-events/2480644/Four highly regarded optometrists have been named as panelists for a pair of Contact Lens Institute online learning events scheduled for March 3. Drs. Chris Lievens, Mark Schaeffer, Bridgitte Shen Lee, and Jason Tu will headline “
- Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conferencehttps://modernod.com/news/clearside-biomedicals-suprachoroidal-injection-platform-featured-at-the-angiogenesis-exudation-and-degeneration-2022-virtual-conference/2480642/Clearside Biomedical announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12,
- Regenxbio Presents Positive Interim Data From Phase 2 ALTITUDE Trial of RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-presents-positive-interim-data-from-phase-3-altitude-trial-of-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery/2480639/Regenxbio announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogene
- Glaukos Announces Executive Leadership Changeshttps://modernod.com/news/glaukos-announces-executive-leadership-changes/2480628/Glaukos announced several executive leadership changes to support the company’s future growth and strategic plans. The following executive changes will become effective on April 1, 2022: Joseph Gilliam will assume the new role of President and Chief Operating Officer.